Albany, New York, 29 April 2015 : Market Research Reports Search Engine
(MRRSE), announces the addition of a new report titled ‘Frontier
Pharma: Pain - Identifying and Commercializing First-in-Class Innovation’ to its database. The report, published
by Market Research Reports Search Engine (MRRSE), offers a brief introduction
to pain and its various subtypes before offering a lowdown on the treatment
algorithms and pharmacotherapy for the indication. Besides other important
facets of the pain market, the report also discusses how the molecular target
landscape has witnessed a change. The most important aspects of innovation have
been investigated further to help analysts emerge with specific details about
the stage of development of these therapies, the molecular target and molecule
type.
The deal and co-development
landscape of the pain therapies
market has been meticulously
assessed; critical changes in the licensing environment are also reviewed.
According to the findings of
the report, the active pain pipeline is composed of as many as 796 products at
all development stages. This gives evidence of the highly diverse array of
molecular targets that are present in the active pain pipeline. The report
identifies 122 first-in-class active-stage development programs. These programs
account for about 13.6% of the entire pipeline, demonstrating the high degree
of innovation that exists within the active pain pipeline.
The pain therapeutics market,
on the other hand, presents a divergent picture. A paltry rate of innovation
has been reported from the pain therapeutics market over the last decade
because of the continued dominance of traditional active pharmaceutical
ingredients.
Opioids dominate the segment
for moderate-to-severe pain. But their potential for abuse has prompted
pharmacos to reformulate opioids into abuse-resistant version. In the mild pain
treatment segment, non-steroidal anti-inflammatory drugs (NSAID) enjoy a
leading position. However, these drugs do not provide adequate treatment for
certain types of chronic pain and neuropathic subtypes.
While most first-in-class
innovation programs in the active pain pipeline still fall within the limits of
early-stage development, the majority of these programs are centered on novel
molecular targets for neuropathic pain – the most incapacitating and complex
variety of chronic pain. Market players focusing on these drug classes could
possibly alter the course of the pain therapies market.
The pain deals ecosystem has
been abuzz with several licensing and development agreements being signed over
the last decade. The report finds that during this period, 112 co-development
and 261 licensing agreements were signed. Despite investment dollars being
channeled into the pain therapies market, there has been a conspicuous lack of deals
and agreements for first-in-class products. Going forward, the unmet need for
therapies to treat chronic pain and breakthroughs in research related to
pathophysiologies of pain-subtypes will help foster more licensing and
co-development partnerships.
Table
of Contents
1 Table of Contents
1.1 List of Figures
2
Executive Summary
2.1 Large and Innovative Pipeline
2.2 Highly Diversified Range of Innovative Programs in Early
Pipeline and in Granted Patents
2.3 Active Deals landscape with Numerous Investment
Oppertunities
3 The
Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Development Remains
Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class
Product Innovation
3.5 Sustained Innovation
3.6 GBI Research Report Guidance
Send An
Enquiry : http://www.mrrse.com/enquiry/108
4
Clinical and Commercial Landscape
4.1 Disease Overview
4.1.1 Chronic and Neuropathic Pain
4.1.2 Disease Pathophysiology
4.1.3 Diagnosis
4.1.4 Treatment Option
4.1.5 Treatment Algorithm
4.2 Overview of Marketed Products for Pain
4.2.1 Analgesic Product Categories
4.2.2 Molecular Type Analysis
4.2.3 Molecular Target Analysis
4.2.4 Current Unmet Needs
5
Assessment of Pipeline Product Innovation
5.1 Pain Pipeline by Molecule Type, Phase and Therapeutic
Targets
5.2 Comparative Distribution of Programs between the Pain Market
and Pipeline by Therapeutic Target Family
5.3 First-in-Class Pipeline Programs
5.4 First-in-Class Targets by Pain Subtype
6 Pain
Patent Analysis
7
First-in-Class Target and Pipeline Program Evaluation
7.1 Pipeline Programs Targeting Fatty Acid Amide Hydrolase
7.2 Pipeline Programs Targeting Purinoceptor 3
7.3 Pipeline Programs Targeting Purinoceptor 7
7.4 Pipeline Programs Targeting Purinoceptor 4
7.5 Pipeline Programs Targeting Orexin Receptor Type 1
7.6 Pipeline Programs Targeting Neuronal Nitric Oxide Synthase
7.7 Pipeline Programs that Target Tropomyosin-Related Kinase A
7.8 Pipeline Programs that Target C-C Chemokine Receptor 2
7.9 Pipeline Programs that Target Endomorphin 2
7.10 Pipeline Programs that Target Protein Kinase C?
7.11 Pipeline Programs that Target Opioid Receptor-Like-1
Receptor
7.12 Pipeline Programs that Target Bradykinin B1 Receptor
7.13 Pipeline Programs Targeting Galanin Receptor 2
7.14 Pipeline Programs Targeting Nerve Growth Factor
8 Deals
and Strategic Consolidations
8.1 Industry Industry-wide First-in-Class Deals
8.2 Pain Deals Landscape
8.3 Licensing Deals
8.3.1 Molecule Type
8.3.2 Mechanism of Action
8.4 Co-development Deals
8.4.1 Molecule Type
8.4.2 Mechanism of Action
8.5 First-in-Class Programs Not Involved in Licensing or
Co-Development Deals
9
Appendix
9.1 Abbreviations
9.2 References
9.3 Contact Us
9.4 Disclaimer
About Us
Market Research Reports Search Engine (MRRSE) is an
industry-leading database of market intelligence reports. Headquartered in New
York, U.S., MRRSE is driven by a stellar team of research experts and advisors
trained to offer objective advice. Our sophisticated search algorithm returns
results based on the report title, geographical region, publisher, or other
keywords.
MRRSE partners exclusively with leading global publishers to
provide clients single-point access to top-of-the-line market research. MRRSE’s
repository is updated every day to keep its clients ahead of the next new trend
in market research, be it competitive intelligence, product or service trends
or strategic consulting.
Contact
Us:
State
Tower,
90
State Street,
Suite
700,
Albany
NY - 12207
United
States
Tel:
+1-518-618-1030
Email:
sales@mrrse.com
Website:
http://www.mrrse.com/
No comments:
Post a Comment